José Manuel Entenza

José Manuel Entenza

Auto-generated profile, based on publicly available information

José Manuel Entenza

Department of Fundamental Microbiology, University of Lausanne, CH-1015 Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2005 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JEJ. M. Entenza
J. M. Entenza
JLJ. M. Loeffler
J. M. Loeffler
DGDenis Grandgirard
Denis Grandgirard
VFV. A. Fischetti
V. A. Fischetti
PMP. Moreillon
P. Moreillon
Cpl-1, a pneumococcal phage lytic enzyme, was tested in rats with experimental endocarditis due to Streptococcus pneumoniae WB4. High-dose regimen Cpl-1 eliminated pneumococci from blood within 30 min and decreased bacterial titers in vegetations (>4 log 10 CFU/g) within 2 h. Rapid bacterial lysis induced by Cpl-1 treatment increased cytokine secretion noticeably.

6 February 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YLYu Larpin
Yu Larpin
FOFrank Oechslin
Frank Oechslin
PMPhilippe Moreillon
Philippe Moreillon
Grégory ReschGrégory Resch
Grégory Resch
JEJosé Manuel Entenza
José Manuel Entenza
SMStefano Mancini
Stefano Mancini
The recent rise of multidrug-resistant Gram-negative bacteria represents a serious threat to public health and makes the search for novel effective alternatives to antibiotics a compelling need. Bacteriophage (Phage) lysins are enzymes that hydrolyze the cell wall of bacteria and represent a promising alternative to tackle this ever-increasing problem. Despite their use is believed to be restricted to Gram-positive bacteria, recent findings have shown that they can also be used against Gram-negative bacteria. By using a phage genome-based screening approach, we identified and characterized a novel lysin, PlyE146, encoded by an Escherichia coli prophage and with a predicted molecular mass of ca. 17 kDa. PlyE146 is composed of a C-terminal cationic peptide and a N-terminal N-acetylmuramidase domain. Histidine-tagged PlyE146 was overexpressed from a plasmid in Lactococcus lactis NZ9000 and purified by NI-NTA chromatography. PlyE146 exhibited in vitro optimal bactericidal activity against E. coli K12 (3.6 log10 CFU/mL decrease) after 2 h of incubation at 37°C at a concentration of 400 μg/mL in the absence of NaCl and at pH 6.0. Under these conditions, PlyE146 displayed antimicrobial activity towards several other E. coli, Pseudomonas aeruginosa (3 to 3.8-log10 CFU/mL decrease) and Acinetobacter baumannii (4.9 to >5-log10 CFU/mL decrease) strains. Therefore, PlyE146 represents a promising therapeutic agent against E. coli, P. aeruginosa and A. baumannii infections. However, further studies are required to improve the efficacy of PlyE146 under physiological conditions.

1 July 2009 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
JEJ.M. Entenza
J.M. Entenza
PMP. Moreillon
P. Moreillon

20 January 2006 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
LSLaurence Senn
Laurence Senn
JEJosé M Entenza
José M Entenza
Gilbert GREUBGilbert GREUB
Gilbert GREUB
KJKatia Jaton
Katia Jaton
AWAline Wenger
Aline Wenger
GPGuy Prod'Hom
Guy Prod'Hom
Background: Abiotrophia and Granulicatella species, previously referred to as nutritionally variant streptococci (NVS), are significant causative agents of endocarditis and bacteraemia. In this study, we reviewed the clinical manifestations of infections due to A. defectiva and Granulicatella species that occurred at our institution between 1998 and 2004. Methods: The analysis included all strains of NVS that were isolated from blood cultures or vascular graft specimens. All strains were identified by 16S rRNA sequence analysis. Patients' medical charts were reviewed for each case of infection. Results: Eleven strains of NVS were isolated during the 6-year period. Identification of the strains by 16S rRNA showed 2 genogroups: Abiotrophia defectiva (3) and Granulicatella adiacens (6) or "para-adiacens" (2). The three A. defectiva strains were isolated from immunocompetent patients with endovascular infections, whereas 7 of 8 Granulicatella spp. strains were isolated from immunosuppressed patients, mainly febrile neutropenic patients. We report the first case of "G. para-adiacens" bacteraemia in the setting of febrile neutropenia. Conclusion: We propose that Granulicatella spp. be considered as a possible agent of bacteraemia in neutropenic patients.

1 August 2014 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
TVTiago Rafael Veloso
Tiago Rafael Veloso
YQYok-Ai Que
Yok-Ai Que
ACAziz Chaouch
Aziz Chaouch
MGMarlyse Giddey
Marlyse Giddey
JVJacques Vouillamoz
Jacques Vouillamoz
JEJosé Manuel Entenza
José Manuel Entenza
Background. Infective endocarditis (IE) mostly occurs after spontaneous low-grade bacteremia. Thus, IE cannot be prevented by circumstantial antibiotic prophylaxis. Platelet activation following bacterial-fibrinogen interaction or thrombin-mediated fibrinogen-fibrin polymerization is a critical step in vegetation formation. We tested the efficacy of antiplatelet and antithrombin to prevent experimental IE. Methods. A rat model of experimental IE following prolonged low-grade bacteremia mimicking smoldering bacteremia in humans was used. Prophylaxis with antiplatelets (aspirin, ticlopidine [alone or in combination], eptifibatide, or abciximab) or anticoagulants (antithrombin dabigatran etexilate or anti–vitamin K acenocoumarol) was started 2 days before inoculation with Streptococcus gordonii or Staphylococcus aureus. Valve infection was assessed 24 hours later. Results. Aspirin plus ticlopidine, as well as abciximab, protected 45%–88% of animals against S. gordonii and S. aureus IE (P < .05). Dabigatran etexilate protected 75% of rats against IE due to S. aureus (P < .005) but failed to protect against S. gordonii (<30% protection). Acenocoumarol was ineffective. Conclusions. Antiplatelet and direct antithrombin agents may be useful in the prophylaxis of IE in humans. In particular, the potential dual benefit of dabigatran etexilate might be reconsidered for patients with prosthetic valves, who require life-long anticoagulation and in whom S. aureus IE is associated with high mortality.

1 May 2011 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
TVT. R. Veloso
T. R. Veloso
MAM. Amiguet
M. Amiguet
VRV. Rousson
V. Rousson
MGM. Giddey
M. Giddey
JVJ. Vouillamoz
J. Vouillamoz
JEJ. M. Entenza
J. M. Entenza
Transient high-grade bacteremia following invasive procedures carries a risk of infective endocarditis (IE). This is supported by experimental endocarditis. On the other hand, case-control studies showed that IE could be caused by cumulative exposure to low-grade bacteremia occurring during daily activities. However, no experimental demonstration of this latter possibility exists. This study investigated the infectivity in animals of continuous low-grade bacteremia compared to that of brief high-grade bacteremia. Rats with aortic vegetations were inoculated with Streptococcus intermedius , Streptococcus gordonii or Staphylococcus aureus (strains Newman and P8). Animals were challenged with 10 3 to 10 6 CFU. Identical bacterial numbers were given by bolus (1 ml in 1 min) or continuous infusion (0.0017 ml/min over 10 h). Bacteremia was 50 to 1,000 times greater after bolus than during continuous inoculation. Streptococcal bolus inoculation of 10 5 CFU infected 63 to 100% vegetations compared to 30 to 71% infection after continuous infusion ( P > 0.05). When increasing the inoculum to 10 6 CFU, bolus inoculation infected 100% vegetations and continuous infusion 70 to 100% ( P > 0.05). S. aureus bolus injection of 10 3 CFU infected 46 to 57% valves. This was similar to the 53 to 57% infection rates produced by continuous infusion ( P > 0.05). Inoculation of 10 4 CFU of S. aureus infected 80 to 100% vegetations after bolus and 60 to 75% after continuous infusion ( P > 0.05). These results show that high-level bacteremia is not required to induce experimental endocarditis and support the hypothesis that cumulative exposure to low-grade bacteremia represents a genuine risk of IE in humans.